Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
NCT Number: NCT07031596
1. Study Background and Purpose Obesity is a complex chronic disease closely linked to comorbidities such as cardiovascular disease, hypertension, and diabetes. With lifestyle changes, obesity prevalence continues to rise. Current treatments focus on weight loss through dietary control and exercise, but weight regain is common due to metabolic adaptations (e.g., post-caloric restriction). Gut microbiota play a critical role in weight management, and probiotics may reduce weight regain by modulating appetite and metabolism. Studies suggest probiotics enhance satiety and reduce appetite. This study aims to evaluate the potential of probiotics in obesity management, specifically their impact on gut microbiota modulation and hormonal regulation to mitigate weight regain. Ethical approval has been obtained from the Peking Union Medical College Hospital Ethics Committee. 2. Study Design
This 198-participant, randomized, interventional trial will assign subjects to three groups (1:1:1 ratio):
Placebo group (maltodextrin-based placebo) Probiotic Group 1 Probiotic Group 2 Randomization will be conducted via sealed envelopes (no researcher/participant bias). All groups receive standardized nutritional counseling, caloric restriction plans, and body composition assessments. Probiotics (produced by Shenzhen BaoShiJian Biotechnology Co., Ltd., compliant with standard Q/BSJ 0023S-2024) will be administered orally (2 bottles twice daily) for 84 days . 3. Study Procedure Informed Consent : Required before participation. Screening Phase : Demographic history, medical records, concomitant medications, validated questionnaires, body composition analysis, and blood/urine/stool tests.
Intervention : Daily probiotic or placebo intake for 84 days. Follow-ups : Visits at Day 42 and Day 85 for adherence checks, anthropometric measurements, and repeat testing. 4. Study Completion Duration : 84 days. Post-Study : Placebo group receives 1-month free probiotic supply; others return to standard care. A 30-day post-study follow-up (phone/WeChat) will assess safety.
Withdrawal : Participants may exit anytime. Investigators may withdraw participants for safety reasons. 5. Potential Benefits Personalized nutrition counseling and body composition reports. Free clinical evaluations and health coaching. Contribution to novel weight management strategies for weight-cycling populations. 6. Risks and Discomforts Adverse Events : Gastrointestinal symptoms or discomfort. Immediate reporting required for medical management.
Inconveniences :
3 on-site visits (blood/urine/stool tests, anthropometry) with fasting blood draws (~7-20 mL/session).
1 telehealth visit (25 min questionnaire). Daily diary cards. Compensation : 150 RMB travel reimbursement + study-provided scales. 7. Alternative Options
Participants may opt for:
Intermittent fasting. Pharmacotherapy (e.g., GLP-1 agonists). Standard dietary recommendations. 8. New Information Any significant findings during the trial will be communicated to participants, who may choose to continue or withdraw.
9. Costs and Reimbursement No-cost : All investigational products (probiotics/placebo), lab tests, and body composition analyses.
Reimbursement : 150 RMB travel compensation + study tools (body fat scale, food scale, tape measure).
10. Adverse Event Policy All injuries attributed to the intervention will be covered by Shenzhen BaoShiJian Biotechnology Co., Ltd. 's insurance. Legal liability extends beyond insurance coverage.
Trial opening soon.
Get Notified18 year–60 year
All sexes
Interventional
Not applicable
Beijing, Beijing Municipality, 100730, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Documented weight loss attempts within the past 2 years (≥3 episodes) with ≥5% body weight fluctuation.
Exclusion criteria
Triglycerides >2.5× upper limit of normal (ULN) Cholesterol >2.5× ULN (method-dependent) Fasting whole-blood glucose >11.1 mmol/L Uric acid >2× ULN
Product : WONDERLAB SHAPE100™ Ready-to-Eat Probiotic Food (S100). Ingredients : Stachyose, fructooligosaccharides, isomaltooligosaccharides, maltodextrin, Lactiplantibacillus plantarum CECT7527, Lactiplantibacillus plantarum CECT7528, Lactiplantibacillus plantarum CECT7529, Lactobacillus acidophilus GOLDGUT-LA100, and Epigallocatechin gallate (EGCG).
Administration : Twice daily (2 bottles per dose) after meals for 12 weeks.
Other names: Calorie-Restricted Diet
Product : WONDERLAB SHAPE100™ Ready-to-Eat Probiotic Food (S100) + WONDERLAB Weight Management Probiotic Food.
Ingredients :
S100 Components : As above. Weight Management Components : Isomaltooligosaccharides, fructooligosaccharides, maltodextrin, Lactobacillus fermentum K7-Lb1, Lactobacillus fermentum K8-Lb1, Lactobacillus fermentum K11-Lb3, Euglena gracilis, and phosphatidylserine.
Administration : Twice daily (2 bottles per dose) after meals for 12 weeks.
Other names: Calorie-Restricted Diet
Daily oral administration of maltodextrin-based placebo (identical in taste, appearance, and packaging to probiotic products) twice daily (2 bottles per dose) for 12 weeks.
Other names: Calorie-Restricted Diet
Time frame: From baseline (D0) to end of intervention (D85 ±7 days)
Proportion of participants achieving ≥5% reduction in body weight from baseline (D0) to end of intervention (D85).
Time frame: From baseline (D0) to end of intervention (D85 ±7 days)
The PFS assesses hedonic hunger on a 15-75 scale. Higher scores indicate greater responsiveness to the food environment.
Time frame: From baseline (D0) to end of intervention (D85 ±7 days)
Measured in fasting state using immunoassay.Unit of Measure: μU/mL
Time frame: From baseline (D0) to end of intervention (D85 ±7 days)
Measured in kilograms using a calibrated digital scale.
Time frame: From baseline (D0) to end of intervention (D85 ±7 days)
Fasting triglycerides measured via enzymatic assay.Unit of Measure: mmol/L
Time frame: From baseline (D0) to end of intervention (D85 ±7 days)
Microbial α-diversity will be assessed using the Shannon index. Higher values indicate greater microbial diversity.
Time frame: From baseline (D0) to end of intervention (D85 ±7 days)
adverse events will be recorded and graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Time frame: From baseline (D0) to end of intervention (D85 ±7 days)
The DEBQ includes three subscales: emotional, external, and restrained eating. Each subscale is scored from 1 (low tendency) to 5 (high tendency). Higher scores indicate a stronger presence of the eating behavior.
Time frame: D0 to D85 ±7 days
Active ghrelin measured via ELISA.Unit of Measure: pg/mL
Time frame: From baseline (D0) to end of intervention (D85 ±7 days)
LDL-C calculated using Friedewald formula or direct measurement.Unit of Measure: mmol/L
Time frame: From baseline (D0) to end of intervention (D85 ±7 days)
GI symptoms including bloating and diarrhea will be rated on a 5-point Likert scale (1 = none, 5 = very severe). Higher scores indicate more severe symptoms
Contact information is provided by the study sponsor or research team.
Peking Union Medical College Hospital
Other
Study on the Weight Loss Effects and Mechanisms of Probiotic Preparation Intervention in Weight Cyclers: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Acronym: Probiotic
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07011628
Bariatric Surgery, Body Weight
Nashville, Tennessee, United States
View Trial DetailsNCT07542327
Body Weight, Nutrition Disorders
Esbjerg, Region Syddanmark, Denmark
View Trial DetailsNCT07027969
Arrhythmias, Cardiac, Atrial Fibrillation
Cleveland, Ohio, United States
View Trial DetailsNCT06795360
Body Weight, Body Weight Changes
View Trial Details